“Crohn’s Disease Pipeline Insight, 2024″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Crohn’s Disease Market.
The Crohn’s Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Request for Sample Report here @ Crohn’s Disease Pipeline Insight
Some of the key takeaways from the Crohn’s Disease Pipeline Report:
- Crohn’s Disease Companies across the globe are diligently working toward developing novel Crohn’s Disease treatment therapies with a considerable amount of success over the years.
- Crohn’s Disease companies working in the treatment market are Janssen, RedHill Biopharma, Amgen, Pfizer, Prometheus Biosciences, AgomAb Therapeutics, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, HAV Vaccines Ltd, Enzo Biochem Inc., Stero Biotechs, Reistone Biopharma Company Limited, Qu Biologics, Pfizer, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, Soligenix, Immunic, Pfizer, Atlantic Healthcare, 4D Pharma, Landos Biopharma, Janssen, Roche, Eisai, Bristol-Myers Squibb, Iltoo Pharma, Suzhou Connect Biopharmaceuticals, Theravance Biopharma, TaiwanJ Pharmaceuticals, Celularity, Cerecor, GlaxoSmithKline, KangStem Biotech, Immunic, Alpha Cancer Technologies, Koutif Therapeutics, Tract Therapeutics, Trio medicines, ChemoCentryx, Algernon Pharmaceuticals, Neuclone, JHL Biotech, Innovative Pharmacological Research (IPHAR) Co Ltd, Innovation Pharmaceuticals, Exeliom Biosciences SAS, AbbVie, Finch Therapeutics, Akeso Biopharma, Draconis Pharma, MakScientific, Engitix, Origo Biopharma, Navidea Biopharmaceuticals, Orchard Therapeutics, Xbrane, Thetis Pharmaceuticals, Temisis Therapeutics, Synedgen, Synlogic, Morphic Therapeutic, Metacrine, Curacle, Commence Bio Inc, Cloud Pharmaceuticals, Chong Kun Dang Pharmaceutical Corp, Avobis Bio LLC, Avexegen Therapeutics, Assembly Biosciences, Aibios Co Ltd, Aclaris Therapeutics, Athos Therapeutics, Denali Therapeutics, Educell doo, and others, are developing therapies for the Crohn’s Disease treatment.
- Emerging Crohn’s Disease therapies such as Guselkumab, ABP-654, RHB-104, Etrolizumab, PRA-023, AGMB-129, Filgotinib, Mirikizumab, Ozanimod, Brazikumab, Remestemcel-L, Rifaximin, Foralumab, ABX-464, Etrasimod, CYTO-201, Masitinib, HAV anti-MAP vaccine, Alequel, Cannabidiol, SHR0302, QBECO-SSI, PRV-6527, PF-06651600, MT-1303, TAK-018, SGX203, IMU 838, Alicaforsen, Bacteroides thetaiotaomicron, BT-11, JNJ-64304500, E6011, BMS-986165, Spesolimab, Aldesleukin, CBP-307, TD-1473, JKB-122, PDA-001, MDGN-002, GSK1070806, Furestem-CD, IMU-856, ACT-101, KT-1002, TregCel, TR8, CCX507, NP-178, NeuLara, JHL1255, Anti-inflammatory drug LIS, Brilacidin, Research programme: anti-fibrotic therapeutics Faecalibacterium Prausnitzii, Navitoclax, Research programme: Crohn’s disease therapeutics, AK 101, IBD Program, MAK 11049, GI restricted TGF-β inhibitor, Research programme: mannose receptor-targeted therapeutic agents, Research programme: haematopoietic stem cell based ex vivo gene therapy, Xcimzane, TP317, TEM1657, SYGN 313, SYNB 8802, MORF 057, IBD Program, CU06, MSC1 & MSC2, Phospholipid A2 (PLA2), CKD-506, Implantable cell therapies, Neuregulin-4 (NRG-4), ABBV-154, AIB-301, ATI-2138 ITK/TXK/JAK3 Inhibitor, JAK1/JAK3 Inhibitor, ITK/TXK/JAK3 Inhibitor, ATH-105, ATH-63, DNL975, CrohnArt, and others are expected to have a significant impact on the Crohn’s Disease market in the coming years.
- On February 2024, Janssen Pharmaceutical announced a Phase 3, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Guselkumab in Participants with Moderately to Severely Active Crohn’s Disease.
- On January 2024, AstraZeneca announced a Phase I, randomised, double-blind, placebo controlled study in healthy male and female subjects as well as patients with Crohn’s disease performed at a single study centre.
Crohn’s Disease Overview
Crohn’s disease is a chronic inflammatory bowel disease (IBD) characterized by inflammation of the gastrointestinal tract, commonly affecting the small intestine and colon. Symptoms include abdominal pain, diarrhea (sometimes bloody), fatigue, weight loss, and fever. The exact cause is unknown but likely involves a combination of genetic predisposition, immune system dysfunction, and environmental factors. Diagnosis relies on a combination of medical history, physical examination, blood tests, imaging studies (such as endoscopy and colonoscopy), and sometimes biopsy. Treatment aims to reduce inflammation, relieve symptoms, and prevent complications, and may include medications like corticosteroids, immunosuppressants, biologics, and dietary changes. In severe cases, surgery to remove damaged portions of the intestine may be necessary. Crohn’s disease is a lifelong condition with periods of flare-ups and remission, requiring ongoing management and monitoring by healthcare professionals.
Get a Free Sample PDF Report to know more about Crohn’s Disease Pipeline Therapeutic Assessment- Crohn’s Disease Drugs and Therapies
Crohn’s Disease Route of Administration
Crohn’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Crohn’s Disease Molecule Type
Crohn’s Disease Products have been categorized under various Molecule types, such as
- Oligonucleotide
- Peptide
- Small molecule
Crohn’s Disease Pipeline Therapeutics Assessment
- Crohn’s Disease Assessment by Product Type
- Crohn’s Disease By Stage and Product Type
- Crohn’s Disease Assessment by Route of Administration
- Crohn’s Disease By Stage and Route of Administration
- Crohn’s Disease Assessment by Molecule Type
- Crohn’s Disease by Stage and Molecule Type
DelveInsight’s Crohn’s Disease Report covers around 75+ products under different phases of clinical development like-
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Crohn’s Disease product details are provided in the report. Download the Crohn’s Disease pipeline report to learn more about the emerging Crohn’s Disease therapies – Crohn’s Disease Clinical Trials and FDA Approvals
Crohn’s Disease Pipeline Analysis:
The Crohn’s Disease pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Crohn’s Disease with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Crohn’s Disease Treatment.
- Crohn’s Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Crohn’s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Crohn’s Disease market.
Download Sample PDF Report to know more about Crohn’s Disease drugs and therapies- FDA-approved Crohn’s Disease drugs
Scope of Crohn’s Disease Pipeline Drug Insight
- Coverage: Global
- Key Crohn’s Disease Companies: Janssen, RedHill Biopharma, Amgen, Pfizer, Prometheus Biosciences, AgomAb Therapeutics, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, HAV Vaccines Ltd, Enzo Biochem Inc., Stero Biotechs, Reistone Biopharma Company Limited, Qu Biologics, Pfizer, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, Soligenix, Immunic, Pfizer, Atlantic Healthcare, 4D Pharma, Landos Biopharma, Janssen, Roche, Eisai, Bristol-Myers Squibb, Iltoo Pharma, Suzhou Connect Biopharmaceuticals, Theravance Biopharma, TaiwanJ Pharmaceuticals, Celularity, Cerecor, GlaxoSmithKline, KangStem Biotech, Immunic, Alpha Cancer Technologies, Koutif Therapeutics, Tract Therapeutics, Trio medicines, ChemoCentryx, Algernon Pharmaceuticals, Neuclone, JHL Biotech, Innovative Pharmacological Research (IPHAR) Co Ltd, Innovation Pharmaceuticals, Exeliom Biosciences SAS, AbbVie, Finch Therapeutics, Akeso Biopharma, Draconis Pharma, MakScientific, Engitix, Origo Biopharma, Navidea Biopharmaceuticals, Orchard Therapeutics, Xbrane, Thetis Pharmaceuticals, Temisis Therapeutics, Synedgen, Synlogic, Morphic Therapeutic, Metacrine, Curacle, Commence Bio Inc, Cloud Pharmaceuticals, Chong Kun Dang Pharmaceutical Corp, Avobis Bio LLC, Avexegen Therapeutics, Assembly Biosciences, Aibios Co Ltd, Aclaris Therapeutics, Athos Therapeutics, Denali Therapeutics, Educell doo and others.
- Key Crohn’s Disease Therapies: Guselkumab, ABP-654, RHB-104, Etrolizumab, PRA-023, AGMB-129, Filgotinib, Mirikizumab, Ozanimod, Brazikumab, Remestemcel-L, Rifaximin, Foralumab, ABX-464, Etrasimod, CYTO-201, Masitinib, HAV anti-MAP vaccine, Alequel, Cannabidiol, SHR0302, QBECO-SSI, PRV-6527, PF-06651600, MT-1303, TAK-018, SGX203, IMU 838, Alicaforsen, Bacteroides thetaiotaomicron, BT-11, JNJ-64304500, E6011, BMS-986165, Spesolimab, Aldesleukin, CBP-307, TD-1473, JKB-122, PDA-001, MDGN-002, GSK1070806, Furestem-CD, IMU-856, ACT-101, KT-1002, TregCel, TR8, CCX507, NP-178, NeuLara, JHL1255, Anti-inflammatory drug LIS, Brilacidin, Research programme: anti-fibrotic therapeutics Faecalibacterium Prausnitzii, Navitoclax, Research programme: Crohn’s disease therapeutics, AK 101, IBD Program, MAK 11049, GI restricted TGF-β inhibitor, Research programme: mannose receptor-targeted therapeutic agents, Research programme: haematopoietic stem cell based ex vivo gene therapy, Xcimzane, TP317, TEM1657, SYGN 313, SYNB 8802, MORF 057, IBD Program, CU06, MSC1 & MSC2, Phospholipid A2 (PLA2), CKD-506, Implantable cell therapies, Neuregulin-4 (NRG-4), ABBV-154, AIB-301, ATI-2138 ITK/TXK/JAK3 Inhibitor, JAK1/JAK3 Inhibitor, ITK/TXK/JAK3 Inhibitor, ATH-105, ATH-63, DNL975, CrohnArt, and others.
- Crohn’s Disease Therapeutic Assessment: Crohn’s Disease current marketed and Crohn’s Disease emerging therapies
- Crohn’s Disease Market Dynamics: Crohn’s Disease market drivers and Crohn’s Disease market barriers
Request for Sample PDF Report for Crohn’s Disease Pipeline Assessment and clinical trials – Crohn’s Disease Treatment Market
Table of Contents
1. Crohn’s Disease Report Introduction
2. Crohn’s Disease Executive Summary
3. Crohn’s Disease Overview
4. Crohn’s Disease- Analytical Perspective In-depth Commercial Assessment
5. Crohn’s Disease Pipeline Therapeutics
6. Crohn’s Disease Late Stage Products (Phase II/III)
7. Crohn’s Disease Mid Stage Products (Phase II)
8. Crohn’s Disease Early Stage Products (Phase I)
9. Crohn’s Disease Preclinical Stage Products
10. Crohn’s Disease Therapeutics Assessment
11. Crohn’s Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Crohn’s Disease Companies
14. Crohn’s Disease Key Products
15. Crohn’s Disease Unmet Needs
16 . Crohn’s Disease Market Drivers and Barriers
17. Crohn’s Disease Future Perspectives and Conclusion
18. Crohn’s Disease Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/asco-conference-coverage